Submitting Cancer Data for Meaningful Use
Meaningful Use for the submission of cancer data
The OSDH Central Cancer Registry is receiving submissions of cancer cases data using the latest HL7 (HL7 Clinical Document Architecture (CDA), Release 2.0, Normative Edition (incorporated by reference in § 170.299). Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries, HL7 Clinical Document Architecture (CDA), (incorporated by reference in § 170.299). (electronic version in PDF) with errata) which is available at no cost at the following link: https://www.hl7.org/implement/standards/product_brief.cfm?product_id=98.
The U.S. National Library of Medicine NLM Tools for EHR Certification and Meaningful Use web page provides free access to the SNOMED CT and LOINC vocabulary standards at the following link: http://www.nlm.nih.gov/healthit/meaningful_use.html.
OSDH has developed a new registration website for Public Health Meaningful Use measures and objectives.
Process for Submitting Test Messages to OSDH
1. To begin the process of submitting messages for cancer case reporting, please review tutorial on how to register and then submit registration using the link* provided below.
* If you have previously submitted a registration to OSDH using the old registration form, please email MeaningfulUse@health.ok.gov to obtain login information. Please include the name of the facility registering, facility address, facility phone number and contact person listed on the previous registration. You will receive a response within two business days from an OSDH Meaningful Use team member with further instruction..
2. Once the registration form is received and processed, your registration will be placed in the queue with other registrations. You will be contacted by an OSDH representative to schedule the kickoff meeting. The kickoff meeting will be held via teleconference and you are required to include your vendor in the teleconference. Failing to include your vendor will require placing your registration back into the queue and the kickoff meeting will be rescheduled at a later date.
3. Communication during the testing period is conducted via email with occasional phone calls. If you have any additional questions, please refer to the FAQs or send an email to OSDH Meaningful Use.
Stage 2 alert: If you are participating in Stage 2, you are required to respond to any communication from the public health agency within 30 days. Failure to respond within two 30 day periods will result in failure of Stage 2 requirements.
The following tables detail the Public Health Stage 2 Cancer Reporting Objective:
|Cancer Reporting by Eligible Professionals (EP)|
The capability to identify and report cancer cases to a public health central cancer registry, except when prohibited, and in accordance with applicable law and practice.
Successful ongoing submission of cancer case information from CEHRT to a public health central cancer registry for the entire EHR reporting period.
Any EP that meets at least 1 of the following criteria may be excluded from this objective:
(1) The EP does not diagnose or directly treat cancer;
(2) the EP operates in a jurisdiction for which no public health agency is capable of receiving electronic cancer case information in the specific standards required for CEHRT at the beginning of their EHR reporting period;
(3) the EP operates in a jurisdiction where no PHA provides information timely on capability to receive electronic cancer case information; or
(4) the EP operates in a jurisdiction for which no public health agency that is capable of receiving electronic cancer case information in the specific standards required for CEHRT at the beginning of their EHR reporting period can enroll additional EPs.
|Cancer Reporting by Eligible Professionals (EP) Stage 2 Standard Requirements|
|Stage 2 Public Health MU Objectives||Stage 2 MU Exchange Standard||Stage 2 MU Vocabulary Standard|
|Cancer Reporting||HL7 Clinical Document Architecture (CDA), Release 2.0, Normative Edition (incorporated by reference in § 170.299). Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries, HL7 Clinical Document Architecture (CDA), (incorporated by reference in § 170.299).||
Legislation requiring cancer reporting by EPs exists in 49 states with some variation in specific requirements, per the 2010 Council of State and Territorial Epidemiologists (CSTE) State Reportable Conditions Assessment (SRCA). In order to meet this objective and measure, an EP must use the capabilities and standards of CEHRT 45 CFR 170.314 (f)(5), and (f)(6).
Should you have any questions regarding attestation requirements for the EHR Incentive Program, please contact the appropriate agency below:
Medicare: contact information for CMS Region VI
For specific information about submitting Immunization, Laboratory Result, or Cancer Case messages, CMS offers Frequently Asked Questions.